Table 3.

Cost-effectiveness Scenario Treating Patients Based on an IL28B or NS5A Test

	Cost, $	Incr. Cost, $	QALY	Incr. QALY	ICER, $	% SVR
IL-28B genotype test
Black patients
Not treated	182 000	-	10.98	-	-	0
8-wk	226 000	44 100	15.02	4.04	10 900	93.9
IL28B tested	243 000	16 800	15.11	0.09	196 000	95.9
12-wk	244 000	1800	15.11	0.01	273 000	96.1
Nonblack patients
Not treated	182 000	-	10.98	-	-	0
8-wk	226 000	44 000	15.03	4.06	10 900	94.3
IL28B tested	243 000	16 900	15.11	0.07	Dominated	95.9
12-wk	244 000	18 700	15.12	0.09	218 000	96.2
NS5A test
Not treated	182 000	-	10.98	-	-	0
8-wk	226 000	43 800	15.10	4.13	10 600	95.8
NS5A tested	229 000	3570	15.16	0.06	62 300	97.2
12-wk	244 000	14 900	15.25	0.09	170 000	99.2